Oxford Immunotec Launches T-Cell Select™ to Enable Full Automation of the T-SPOT®.TB Test, Provides Unrivaled Sample Stability and Simplicity of Blood Collection
OXFORD, United KingdomandMARLBOROUGH, Mass., July 31, 2018(GLOBE NEWSWIRE) –Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced the launch of the new CE-marked T-Cell Select kit in Europe and select ROW countries. Using the T-Cell Select kit, for the first time ever, customers will have a fully automated solution for the T-SPOT.TB test. This will simplify workflow, improve throughput, reduce hands-on time and reduce labor costs in performing the T-SPOT.TB test. Furthermore, with the T-Cell Select kit, blood samples collected in a single standard blood tube can now be stored for up to 54 hours at room temperature before use in the T-SPOT.TB test. This further extends the company’s unrivaled simplicity and logistics advantages for customers.
“I’m thrilled to announce the launch of our T-Cell Select product, which is a major step forward in the workflow and automation of our T-SPOT.TB test,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “We believe the multiple advantages brought by this latest evolution of our test will increase use of the T-SPOT.TB test by new and existing customers and enable testing in new locations.”
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company’s first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company’s second product line is a range of assays for tick-borne diseases, such as Lyme disease. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT, T-Cell Select and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, and intentions, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company’s business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the “Risk Factors” section in our filings with the Securities and Exchange Commission (“SEC”). Our filings are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the SEC’s website, www.sec.gov.
Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.
For Media and Investor Inquiries: Karen Koski
VP, Strategy and Investor Relations
Tel: +1 (508) 556-1377 firstname.lastname@example.org
이 사이트는 쿠키를 사용하여 귀하의 컴퓨터에 정보를 저장합니다. 본 사이트를 작동시키기 위해 필수 쿠키가 사용되며, 사용자 경험을 개선하기 위해서는 비-필수 쿠키가 사용됩니다. 쿠키 활성화 / 비활성화동의하기더 알아보기
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.